Liquidia (LQDA) Shares Just Moved, So What Is Driving Attention Now?

Liquidia (LQDA) is back in focus after a global settlement with United Therapeutics cleared all YUTREPIA patent disputes, removed a long running legal overhang, and allowed continued commercial sales for pulmonary arterial hypertension.

Investors have reacted quickly to the settlement, with the share price rising 24.1% over the past week after a sharp 47.1% decline over 30 days and a 56.5% fall over 90 days, while longer term total shareholder returns above 8x over five years point to powerful momentum over time that the recent legal overhang interrupted.

Scan beyond Liquidia’s rebound and line up other healthcare names with similar risk reset potential using our 34 healthcare AI stocks as a curated starting list.

Liquidia has erased part of the legal discount in a single week, yet the share price still trails both analyst targets and some intrinsic value estimates. Has the settlement already paid you most of the upside, or not yet?

Most Popular Narrative: 35% Undervalued

Liquidia’s most followed valuation view pins fair value at $53.50, well above the last close of $34.78. This keeps the stock framed as materially discounted even after the legal overhang cleared.

Rapid early adoption of YUTREPIA, with more than 900 prescriptions and over 550 patient starts in about 11 weeks, points to growing physician and patient acceptance of inhaled treprostinil delivered via PRINT technology. This can support prescription volume and product revenue as awareness broadens across the 6,500 targeted prescribers.

See why 5 investors see Liquidia as 35% undervalued.

Result: Fair Value of $53.50 (UNDERVALUED)

Still, the YUTREPIA label change around lung disease and the heavy reliance on voucher supported early use both sit uncomfortably against the bullish Liquidia narrative.

Find out about the key risks to this Liquidia narrative.

Another View On Liquidia’s Valuation

Multiples tell one story for Liquidia, with a P/E of 22.5x looking expensive against the US Pharmaceuticals average of 15.5x, yet cheaper than peers at 35.3x and below its own fair ratio of 25.4x. That mix points to both risk and room to rerate, so consider which side matters more for you.

To pressure test that question against detailed earnings drivers and peer comparisons, take a closer look at our valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed messages on Liquidia’s value case so far. Move quickly from reading to testing the thesis yourself with the 3 key rewards and 2 important warning signs.

Want More Ideas Beyond Liquidia?

Do not stop your research with Liquidia. Use the same curiosity that brought you here to uncover fresh opportunities that match your risk and return comfort zone.

• Target potential mispricing by scanning a curated pool of quality companies trading below implied fair value through the 33 high quality undervalued stocks.
• Prioritize resilience by filtering for businesses with robust finances and healthier balance sheets using the list of solid balance sheet and fundamentals (25 results).
• Hunt for lesser known opportunities with strong fundamentals before they become crowded by checking the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com